Account Login
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Blueprint Medicines Corp (NQ: BPMC)
70.37 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 7:43 PM EST, Dec 9, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 70.37
Bid (Size) 61.74 (1)
Ask (Size) 70.20 (5)
Prev. Close 70.37
Today's Range 70.37 - 70.37
52wk Range 44.58 - 102.98
Shares Outstanding 43,837,337
Dividend Yield N/A
Performance
YTD
+37.50%
+37.50%
1 Month
-0.85%
-0.85%
3 Month
-3.83%
-3.83%
6 Month
-19.45%
-19.45%
1 Year
+18.83%
+18.83%
Top News
More News
Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis Showing Activity at All Dose Levels Tested
-- Plan to initiate screening in registration-enabling portion of PIONEER trial in indolent SM in first half 2020 -- Read More
from PR Newswire
Blueprint Medicines to Present at Jefferies 2019 London Healthcare Conference
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that Jeff Albers, Blueprint... Read More
from PR Newswire
More News
Read More
Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition
from PR Newswire
Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results
from PR Newswire
Blueprint Medicines to Host R&D Day and Announce Third Quarter 2019 Financial Results on November 5, 2019
from PR Newswire
Blueprint Medicines Announces FDA Intent to Split Avapritinib New Drug Application into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
from PR Newswire
Notable Thursday Option Activity: ETSY, BPMC, ALNY
category Stocks
from Market News Video
FTXH's Holdings Could Mean 15% Gain Potential
category ETFs
from ETF Channel
Ipsen and Blueprint Medicines Announce Exclusive Global License Agreement to Develop and Commercialize BLU-782 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
from Business Wire News Releases
2 Top Biotech Stocks to Buy Right Now
category Market News , BPMC , AMRN
from Motley Fool
Peek Under The Hood: IYY Has 10% Upside
category ETFs
from ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.